{"url":"https://lda.senate.gov/api/v1/filings/cb5ff357-8e2d-41da-ba10-92bf240d70ca/","filing_uuid":"cb5ff357-8e2d-41da-ba10-92bf240d70ca","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2024,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/cb5ff357-8e2d-41da-ba10-92bf240d70ca/print/","filing_document_content_type":"text/html","income":null,"expenses":"230000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Frank Purcell","dt_posted":"2025-01-21T12:32:26-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"10710 Midlothian Turnpike","registrant_address_2":"Suite 430","registrant_different_address":false,"registrant_city":"Richmond","registrant_state":"VA","registrant_zip":"23235","registrant":{"id":401103976,"url":"https://lda.senate.gov/api/v1/registrants/401103976/","house_registrant_id":null,"name":"INDIVIOR INC","description":"pharmaceutical addiction treatment","address_1":"10710 Midlothian Turnpike","address_2":"Suite 430","address_3":null,"address_4":null,"city":"Richmond","state":"VA","state_display":"Virginia","zip":"23235","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"SCOTT JAUCH","contact_telephone":"+1 804-914-7930","dt_updated":"2026-07-22T20:03:36.647214-04:00"},"client":{"id":200553,"url":"https://lda.senate.gov/api/v1/clients/200553/","client_id":12,"name":"INDIVIOR INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"VA","state_display":"Virginia","country":"US","country_display":"United States of America","ppb_state":"VA","ppb_state_display":"Virginia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-03-15"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"SUPPORT for Patients and Communities Reauthorization Act (HR 4531 / S 2433, S 3106, S 3393); HEAL Act (HR 4007 / S 2809); PAHPA Act (HR 4421 / S 2333); Reentry Act (HR 2400 / S 1165); Due Process Continuity of Care Act (HR 3074 / S 971); FY25 appropriations for Labor-HHS-Education, Military Construction & Veterans Affairs, and Commerce-Justice-Science; DEA rulemaking on telemedicine prescribing of controlled substances (RIN #1117-AB40); CMS Physician Fee Schedule CY25 Proposed Rule (RIN #0938-AV33);Continuing appropriations for FY25 (HR 9747, HR 10545)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138362,"prefix":"mr","prefix_display":"MR.","first_name":"FRANK","nickname":null,"middle_name":"J.","last_name":"PURCELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}